An observational study in Pituitary, sponsored by Azienda Ospedaliero-Universitaria di Modena. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-14.
Sponsored by Azienda Ospedaliero-Universitaria di Modena · Observational
Among 10 studies in Pituitary Diseases with a site in Italy — 5 open to participants now, 5 under way, 1 of them phase 3. Pituitary Diseases · Italy.
Among the 10 studies in Pituitary Diseases with a site in Italy, this one is the only one that started in 2022, is one of 5 observational ones, and was the 7th registered.
74 studies on the registry are indexed under Pituitary Diseases; 15 are open to participants now.
Browse Pituitary Diseases studies →5 of the 10 studies in Pituitary Diseases with a site in Italy are open now. Recruiting first, the newest first:
Debiopharm International SA · Sites in Italy, United States, Austria and 18 more countries
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
RECORDATI GROUP · Sites in Italy, United States, Belgium and 4 more countries
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 12 Pituitary Diseases studies recruiting now, 6 (50%) set no upper age limit and 3 (25%) stop at 75 or younger; 3 take children under 18; 0 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2022.
This study's planned enrollment of 1,500 is above the median of 292 across 31 observational studies indexed under Pituitary Diseases.
Median enrollment 119 across the 5 interventional studies, 1,100 across the 5 observational. Of the 4 that completed or were terminated, 3 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 8 most frequent:
Azienda Ospedaliero-Universitaria di Modena is the lead sponsor of 48 studies on the registry; 20 are open to participants now.
Azienda Ospedaliero-Universitaria di Modena has 1 study filed under Pituitary Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in Pituitary Diseases with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03708900RECORDATI GROUPPharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome | 2027-07-21 |
Among the 10 studies in Pituitary Diseases with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an observational, longitudinal, single-center study.
The study is divided in two phases:
An anonymized database will be created to collect the data of the patients. In particular, the data collected for each patient will include: personal data, data relating to pituitary pathology, symptoms at diagnosis, physical examination, radiological imaging, visual field data, data on surgical intervention, data on histological examination, biohumoral examinations, hormone tests, densitometric data, data on replacement therapies, medical therapies or other pharmacological therapies, data on comorbidities.
Patients affected by pituitary disorders who attended Unit of Endocrinology of Azienza Ospedaliero-Universitaria di Modena
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Characterization of pituitary patients
The primary aim of the study is to characterize subjects with pituitary disease by collecting anamnestic, clinical, biohumoral, radiological data, and data related to the treatment approach, in terms of surgery, medical therapies and/or hormone replacement therapies.
Time frame: 10 years
Management of pituitary patients
The second aim is to integrate these data with current knowledge, in order to improve the clinical-diagnostic-therapeutic management of patients suffering from pituitary diseases, as well as to identify risk factors for the development of the disease.
Time frame: 10 years
Started Oct 2022 (actual). Primary completion is estimated for Oct 2031, 108 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Azienda Ospedaliero-Universitaria di Modena